Bevacizumab in metastatic colorectal cancer and other settings Report uri icon

Overview

MeSH Major

  • Aging
  • Antineoplastic Agents
  • Neoplasms

abstract

  • A landmark study in the treatment of colon cancer is the first to document the clinical benefit of antiangiogenic therapy. Bevacizumab has also shown promising activity in studies of non-small cell lung cancer and renal cell carcinoma, but the benefits and toxicities need to be explored further.

publication date

  • November 2004

Research

keywords

  • Report

Additional Document Info

volume

  • 1

number

  • 4